JP2008050375A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008050375A5 JP2008050375A5 JP2007294088A JP2007294088A JP2008050375A5 JP 2008050375 A5 JP2008050375 A5 JP 2008050375A5 JP 2007294088 A JP2007294088 A JP 2007294088A JP 2007294088 A JP2007294088 A JP 2007294088A JP 2008050375 A5 JP2008050375 A5 JP 2008050375A5
- Authority
- JP
- Japan
- Prior art keywords
- drug carrier
- vitamin
- activity
- analog
- inhibitors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007294088A JP4533420B2 (ja) | 2004-12-22 | 2007-11-13 | 線維化抑制のための薬物担体および薬物担体キット |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004382791 | 2004-12-22 | ||
| JP2007294088A JP4533420B2 (ja) | 2004-12-22 | 2007-11-13 | 線維化抑制のための薬物担体および薬物担体キット |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006549061A Division JP4121537B2 (ja) | 2004-12-22 | 2005-12-22 | 線維化抑制のための薬物担体および薬物担体キット |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010049297A Division JP5172880B2 (ja) | 2004-12-22 | 2010-03-05 | 線維化抑制のための薬物担体および薬物担体キット |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008050375A JP2008050375A (ja) | 2008-03-06 |
| JP2008050375A5 true JP2008050375A5 (https=) | 2009-12-17 |
| JP4533420B2 JP4533420B2 (ja) | 2010-09-01 |
Family
ID=39234728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007294088A Expired - Fee Related JP4533420B2 (ja) | 2004-12-22 | 2007-11-13 | 線維化抑制のための薬物担体および薬物担体キット |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4533420B2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE056941T2 (hu) | 2004-12-22 | 2022-04-28 | Nitto Denko Corp | Gyógyszerhordozó és gyógyszerhordozó kit fibrózis gátlására |
| US20120269886A1 (en) | 2004-12-22 | 2012-10-25 | Nitto Denko Corporation | Therapeutic agent for pulmonary fibrosis |
| US9572886B2 (en) | 2005-12-22 | 2017-02-21 | Nitto Denko Corporation | Agent for treating myelofibrosis |
| TWI407971B (zh) | 2007-03-30 | 2013-09-11 | 日東電工股份有限公司 | Cancer cells and tumor-related fibroblasts |
| EP2368989A4 (en) | 2008-11-26 | 2012-09-26 | Chugai Pharmaceutical Co Ltd | OLIGORIBONUCLEOTID- BZW. PEPTID NUCLEIC ACID TO INHIBIT THE ACTIVITY OF HEPATITIS C VIRUS |
| CN102292069B (zh) | 2008-11-26 | 2014-07-30 | 中外制药株式会社 | 囊泡制剂 |
| CN105473147A (zh) * | 2013-04-24 | 2016-04-06 | 萨克生物研究学院 | 维生素d受体/smad基因组回路门纤维化反应 |
| WO2019023149A1 (en) | 2017-07-24 | 2019-01-31 | Salk Institute For Biological Studies | USE OF BROMODOMAIN-CONTAINING PROTEIN-9 ANTAGONISTS IN ASSOCIATION WITH VITAMIN D RECEPTOR AGONISTS IN THE TREATMENT OF DIABETES |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4911928A (en) * | 1987-03-13 | 1990-03-27 | Micro-Pak, Inc. | Paucilamellar lipid vesicles |
| US20020012998A1 (en) * | 2000-03-29 | 2002-01-31 | Igor Gonda | Cationic liposomes |
| JP2002047211A (ja) * | 2000-08-04 | 2002-02-12 | Japan Science & Technology Corp | 脂溶性物質と生理活性高分子物質結合体および細胞核内への導入方法 |
| HUE056941T2 (hu) * | 2004-12-22 | 2022-04-28 | Nitto Denko Corp | Gyógyszerhordozó és gyógyszerhordozó kit fibrózis gátlására |
-
2007
- 2007-11-13 JP JP2007294088A patent/JP4533420B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011201890A5 (https=) | ||
| JP2008050375A5 (https=) | ||
| JP2010138188A5 (https=) | ||
| Olejarz et al. | Exosomes in angiogenesis and anti-angiogenic therapy in cancers | |
| Sadakierska-Chudy | MicroRNAs: diverse mechanisms of action and their potential applications as cancer epi-therapeutics | |
| Rosińska et al. | Tumor vessels fuel the fire in glioblastoma | |
| Zhang et al. | Mechanisms of angiogenesis in tumour | |
| Kaur et al. | Modified mRNA as a therapeutic tool for the heart | |
| Liu et al. | Targeted delivery of antisense inhibitor of miRNA for antiangiogenesis therapy using cRGD-functionalized nanoparticles | |
| Kouri et al. | miRNA-182 and the regulation of the glioblastoma phenotype-toward miRNA-based precision therapeutics | |
| Hamada et al. | Novel therapeutic strategies targeting tumor-stromal interactions in pancreatic cancer | |
| Kheshtchin et al. | Targeting hypoxia and hypoxia‐inducible factor‐1 in the tumor microenvironment for optimal cancer immunotherapy | |
| Wu et al. | Improving the intracellular drug concentration in lung cancer treatment through the codelivery of doxorubicin and miR-519c mediated by porous PLGA microparticle | |
| Spugnini et al. | Preclinical models in electrochemotherapy: the role of veterinary patients | |
| RU2017136720A (ru) | Средство для лечения фиброза почек | |
| Song et al. | Tetrahedral framework nucleic acid delivered RNA therapeutics significantly attenuate pancreatic cancer progression via inhibition of CTR1-dependent copper absorption | |
| Beigi et al. | Lipid-based nanocarriers for targeted gene delivery in lung cancer therapy: exploring a novel therapeutic paradigm | |
| Obisi et al. | Unveiling the future of cancer stem cell therapy: a narrative exploration of emerging innovations | |
| Weintraub et al. | Advances in intravesical therapy for the treatment of non‑muscle invasive bladder cancer | |
| Sun et al. | RNA binding proteins in extracellular vesicles and their potential value for cancer diagnosis and treatment | |
| Gu et al. | EGFR-targeted liposomes combined with ginsenoside Rh2 inhibit triple-negative breast cancer growth and metastasis | |
| Gulati et al. | Exosomes as theranostic targets: Implications for the clinical prognosis of aggressive cancers | |
| Maphutha et al. | The role of the PTEN tumor suppressor gene and its Anti-Angiogenic activity in melanoma and other cancers | |
| Hanieh et al. | Aryl hydrocarbon receptor as an anticancer target: an overview of ten years odyssey | |
| Qi et al. | Metabolic Reprogramming of Cancer‐Associated Fibroblasts: Transforming Tumor Accomplices into Immunotherapeutic Allies |